Authors:
R Jeselsohn, M Cornwell, M Pun, G Buchwalter, M Nguyen, C Bango, Y Huang, Y Kuang, C Paweletz, X Fu, A Nardone, C De Angelis, S Detre, A Dodson, H Mohammed, JS Carroll, M Bowden, P Rao, HW Long, F Li, M Dowsett, R Schiff, M Brown
Journal name: 
Proc Natl Acad Sci U S A
Citation info: 
114(22):E4482-E4491
Abstract: 
The estrogen receptor (ER) drives the growth of most luminal breast cancers and is the primary target of endocrine therapy. Although ER blockade with drugs such as tamoxifen is very effective, a major clinical limitation is the development of endocrine resistance especially in the setting of metastatic disease. Preclinical and clinical observations suggest that even following the development of endocrine resistance, ER signaling continues to exert a pivotal role in tumor progression in the majority of cases. Through the analysis of the ER cistrome in tamoxifen-resistant breast cancer cells, we have uncovered a role for an RUNX2-ER complex that stimulates the transcription of a set of genes, including most notably the stem cell factor SOX9, that promote proliferation and a metastatic phenotype. We show that up-regulation of SOX9 is sufficient to cause relative endocrine resistance. The gain of SOX9 as an ER-regulated gene associated with tamoxifen resistance was validated in a unique set of clinical samples supporting the need for the development of improved ER antagonists.
DOI: 
http://doi.org/10.1073/pnas.1620993114
Research group: 
Carroll Group
E-pub date: 
30 May 2017